# STAT+: Up and down the ladder: The latest comings and goings
Canonical URL: https://biopharmsignal.com/news/MARKET/stat-up-and-down-the-ladder-the-latest-comings-and-goings-d8f5feca
Ticker: MARKET
Company: MARKET
Source: STAT News
Published: 2026-07-24 15:57 EST
Original Source URL: https://www.statnews.com/pharmalot/2026/07/24/up-and-down-the-ladder-rigel-sanofi-pharma-jobs/?utm_campaign=rss
## Summary

From new hires to departures, promotions, and hires, here are the latest comings and goings in the pharma industry.

## Article Body
Alex Hogan/STAT

By Ed Silverman

July 24, 2026

Pharmalot Columnist, Senior Writer

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter .

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them . Don’t be shy. Everyone wants to know who is coming and going.

And here is our regular feature in which we highlight a different person each week. This time around, we note that Rigel Pharmaceuticals hired Alison Hannah as executive vice president and chief medical officer. Previously, she held the same role at CytomX Therapeutics.

But all work and no play can make for a dull chief medical officer.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Pharmalot Columnist, Senior Writer

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter .
## Recent Company News
- 2026-07-24 16:13 EST — [There are already more U.S. measles cases this year than in all of 2025](https://biopharmsignal.com/news/MARKET/there-are-already-more-u-s-measles-cases-this-year-than-in-all-of-2025-ff246e52) — Source: STAT News
- 2026-07-24 15:57 EST — [STAT+: Up and down the ladder: The latest comings and goings](https://biopharmsignal.com/news/MARKET/stat-up-and-down-the-ladder-the-latest-comings-and-goings-d8f5feca) — Source: STAT News
- 2026-07-24 13:41 EST — [STAT+: Fatal gene-editing trial in China raises ethics and oversight questions](https://biopharmsignal.com/news/MARKET/stat-fatal-gene-editing-trial-in-china-raises-ethics-and-oversight-questions-bf72167a) — Source: STAT News
- 2026-07-24 13:28 EST — [STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more](https://biopharmsignal.com/news/MARKET/stat-pharmalittle-we-8217-re-reading-about-an-fda-panel-and-peptides-a-merck-lic-43d923b3) — Source: STAT News
- 2026-07-24 11:59 EST — [A new, separate outbreak of the diarrhea-causing parasite](https://biopharmsignal.com/news/MARKET/a-new-separate-outbreak-of-the-diarrhea-causing-parasite-f394209e) — Source: STAT News
## Related News
- 2026-07-24 16:13 EST — MARKET — [There are already more U.S. measles cases this year than in all of 2025](https://biopharmsignal.com/news/MARKET/there-are-already-more-u-s-measles-cases-this-year-than-in-all-of-2025-ff246e52)
- 2026-07-24 13:41 EST — MARKET — [STAT+: Fatal gene-editing trial in China raises ethics and oversight questions](https://biopharmsignal.com/news/MARKET/stat-fatal-gene-editing-trial-in-china-raises-ethics-and-oversight-questions-bf72167a)
- 2026-07-24 13:28 EST — MARKET — [STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more](https://biopharmsignal.com/news/MARKET/stat-pharmalittle-we-8217-re-reading-about-an-fda-panel-and-peptides-a-merck-lic-43d923b3)
- 2026-07-24 12:00 EST — NAMS — [NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)](https://biopharmsignal.com/news/NAMS/newamsterdam-pharma-and-menarini-group-receive-positive-chmp-opinion-recommendin-6e39bfc3)
- 2026-07-24 11:59 EST — MARKET — [A new, separate outbreak of the diarrhea-causing parasite](https://biopharmsignal.com/news/MARKET/a-new-separate-outbreak-of-the-diarrhea-causing-parasite-f394209e)